Hypera (HYPE3) Q2 2024 earnings summary

Executive summary

• Sell-out increased 6.3% in Q2 2024, driven by chronic and preventive treatments, with a robust innovation pipeline of over 500 products planned for launch in coming years.

• Net revenue reached R$2,188.9 million (BRL 2.2 billion), down 1.9% from 2Q23, reflecting a tough comparison with strong prior-year growth.

• Cash flow from operations hit a record R$624.2 million, up 8.0% year-over-year, aided by inventory reduction.

• Significant investments made in R&D (7–7.2% of net revenue), innovation, and production capacity, including new plant projects and distribution center expansion.

• Interest on Equity of R$184.9 million (R$0.29/share) approved in 2Q24.

Financial highlights

• Gross margin was 60.9% in 2Q24, a decline of 2.3 p.p. (230bps) year-over-year.

• EBITDA margin from continuing operations was 34.5%, down 0.9 p.p. year-over-year.

• Net income from continuing operations was R$491.8 million, down 2.5% year-over-year.

• Free cash flow reached R$458.9 million, up R$113.8 million from 2Q23.

• Marketing expenses ranged from 15.2% to 22% of net revenue, with flexibility to adjust by segment.

Outlook and guidance

• 2024 net revenue guidance is R$8.6 billion, with EBITDA expected at R$3.0 billion and net profit at R$1.85 billion.

• Confident in achieving 2024 guidance, expecting higher sell-out in H2 as influenza market recovers post-El Niño.

• Chronic and preventive treatments expected to drive above-market growth, supported by a strong innovation pipeline.

• Focus remains on reducing inventories to drive operating and free cash flow growth.

• Guidance for 2024 remains unchanged, with focus on operational generation and results.